表紙
市場調查報告書
商品編碼
832988

癌症治療用生技藥品的全球市場:2019年∼2023年

Global Cancer Biologics Market 2019-2023

出版日期: | 出版商: TechNavio (Infiniti Research Ltd.) | 英文 127 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球癌症發病率的上升可能會影響預測期內市場的增長。包括吸煙和污染在內的環境污染和飲食模式的改變預計會直接導致全球癌症發病率的上升。這種情況下最終將促致預測期間癌症生物製劑市場的增長。 Technavio的分析師預測全球癌症治療用生技藥品市場在2023年前,預計將以11%以上的年複合成長率增長。

本報告提供全球癌症治療用生技藥品市場相關調查分析,提供市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

第1章 摘要整理

第2章 報告的範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各產品

  • 市場區隔:各產品
  • 各產品比較:市場規模及預測(2018年∼2023年)
  • 單株抗體
  • 疫苗
  • 細胞/基因治療
  • 其他
  • 市場機會:各產品

第7章 客戶形勢

第8章 地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

第12章 業者情勢

  • 概要
  • 創造性破壞狀況

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.

第14章 附錄

  • 調查方法
  • 簡稱的清單

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR31171

About this market

The rising global incidences of cancer are likely to impact the market's growth during the forecast period. Increasing prevalence of environmental factors including tobacco smoking and pollution and changing dietary patterns are expected to contribute directly to the increased global incidences of cancer. Such rising incidences of this condition will eventually contribute to the cancer biologics market growth during the forecast period. Technavio's analysts have predicted that the cancer biologics market will register a CAGR of over 11% by 2023.

Market Overview

The rising global incidence of cancer

The major etiological factors leading to cancer include genetic mutations, environmental factors such as tobacco smoking and pollution, and changing dietary patterns. The rising prevalence of these factors has directly contributed to the increased global incidence of cancer.

Patient expiry of major cancer biologics

The emergence of biosimilars due to patent expiration of biologics hinder the market growth, despite the increased incidence of cancer during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the cancer biologics market during 2019-2023, view our report.

Competitive Landscape

The market appears to be highly concentrated with the presence of a few market players. Manufacturers in the global cancer biologics market are entering into strategic collaborations to develop or commercialize biologics indicated for the treatment of various types of cancer. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Monoclonal antibodies - Market size and forecast 2018-2023
  • Vaccines - Market size and forecast 2018-2023
  • Cell and gene therapy - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global oncology therapeutics market
  • Exhibit 02: Segments of global oncology therapeutics market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Product - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by product
  • Exhibit 19: Monoclonal antibodies - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: Monoclonal antibodies - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: Vaccines - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Vaccines - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Cell and gene therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Cell and gene therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 26: Others - Year-over-year growth 2019-2023 (%)
  • Exhibit 27: Market opportunity by product
  • Exhibit 28: Customer landscape
  • Exhibit 29: Market share by geography 2018-2023 (%)
  • Exhibit 30: Geographic comparison
  • Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Key leading countries
  • Exhibit 40: Market opportunity
  • Exhibit 41: Biologics in the pipeline for cancer
  • Exhibit 42: List of recently approved cancer biologics by the FDA
  • Exhibit 43: Cancer biologics and their biosimilar versions
  • Exhibit 44: Impact of drivers and challenges
  • Exhibit 45: List of collaborations between manufacturers of cancer biologics
  • Exhibit 46: List of predictive biomarkers for cancer
  • Exhibit 47: Vendor landscape
  • Exhibit 48: Landscape disruption
  • Exhibit 49: Vendors covered
  • Exhibit 50: Vendor classification
  • Exhibit 51: Market positioning of vendors
  • Exhibit 52: Amgen Inc. - Vendor overview
  • Exhibit 53: Amgen Inc. - Business segments
  • Exhibit 54: Amgen Inc. - Organizational developments
  • Exhibit 55: Amgen Inc. - Geographic focus
  • Exhibit 56: Amgen Inc. - Key offerings
  • Exhibit 57: Bristol-Myers Squibb Company - Vendor overview
  • Exhibit 58: Bristol-Myers Squibb Company - Business segments
  • Exhibit 59: Bristol-Myers Squibb Company - Organizational developments
  • Exhibit 60: Bristol-Myers Squibb Company - Geographic focus
  • Exhibit 61: Bristol-Myers Squibb Company - Key offerings
  • Exhibit 62: Eli Lilly and Company - Vendor overview
  • Exhibit 63: Eli Lilly and Company - Business segments
  • Exhibit 64: Eli Lilly and Company - Organizational developments
  • Exhibit 65: Eli Lilly and Company - Geographic focus
  • Exhibit 66: Eli Lilly and Company - Segment focus
  • Exhibit 67: Eli Lilly and Company - Key offerings
  • Exhibit 68: F. Hoffmann-La Roche Ltd - Vendor overview
  • Exhibit 69: F. Hoffmann-La Roche Ltd - Business segments
  • Exhibit 70: F. Hoffmann-La Roche Ltd - Organizational developments
  • Exhibit 71: F. Hoffmann-La Roche Ltd - Geographic focus
  • Exhibit 72: F. Hoffmann-La Roche Ltd - Segment focus
  • Exhibit 73: F. Hoffmann-La Roche Ltd - Key offerings
  • Exhibit 74: Merck & Co., Inc. - Vendor overview
  • Exhibit 75: Merck & Co., Inc. - Business segments
  • Exhibit 76: Merck & Co., Inc. - Organizational developments
  • Exhibit 77: Merck & Co., Inc. - Geographic focus
  • Exhibit 78: Merck & Co., Inc. - Segment focus
  • Exhibit 79: Merck & Co., Inc. - Key offerings
  • Exhibit 80: Validation techniques employed for market sizing